ANZ – Opportunity Approaches

Australia and New Zealand Banking Group is a current holding in our ASX 100 model portfolio.

Pressure from lower interest rates more than offset mortgage repricing benefits for the banks and we’ve seen 10%+ correction across the sector.

ANZ, WBC & NAB remain our preferred exposures and we highlight the buying opportunity which is approaching for ANZ.

Buy ANZ within the $25 – $26 price range.

Banks

Australia and New Zealand Banking Group are the first of the big four banks to report annual profits. There was not much to like in the result, Net Interest Margin pressure along with headwinds on cost control, means the outlook was downbeat.

Macquarie Group’s first-half result is due today and it has guided the 2019-20 profit will be “slightly down” on 2018-19.

The market is certain of a dividend cut at Westpac, which reports November 4.

UBS has warned the second-half of 2018-19 will be remembered as the “high watermark” for the sector, ” as the outlook deteriorates in an ultra-low rate environment.

We prefer the short side of CBA.

 

 

Raytheon – Now Up 20%

Raytheon was a “high conviction” buy expressed on the blog in August. The stock price is now up 20%+ following back-to-back strong quarterly earnings results.

Next year United Technology shareholders will vote on the merger with Raytheon.  We expect this to proceed and anticipate further shareholder value to be unlocked in 2020.

Raytheon is listed on the New York Stock Exchange.  If you would like Investor Signals to manage your international share portfolio, please call us on 1300 614 002.

ResMed – Opportunity Approaches

ResMed is a current holding in our ASX 100 model portfolio.

The company reports 1Q20 earnings on 25 October and we expect revenue growth to be 15%+ and EBIT to be up 10%+ on the same time last year.

We look for an entry-level into RMD on the current price weakness and will update our readers further, following the earnings result.

 

 

Medibank – Algo Buy Signal

Medibank Private is under Algo Engine buy conditions and is a current holding in our ASX 100 model.

At 19x forward earnings and 2 – 4% earnings growth, Medibank is a strong candidate for a covered call overlay to enhance the investment returns.

The stock trades on a forward yield of 3% and when adding a covered call, we can boost the cash flow to 10% on an annualized basis.

Buy MPL at $3.25 and look for a move higher to $3.50 before selling call options.

For more information on this strategy, please call our office on 1300 614 002.